Accueil > Actualité
Actualite financiere : Actualite bourse

Bristol Myers: positive data in kidney cancer

( - Bristol Myers Squibb and Exelixis have announced positive results from the pivotal phase III "CheckMate -9ER" trial evaluating Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) in previously untreated advanced renal cell carcinoma.

The study achieved its primary endpoint of significantly improving progression-free survival, as well as its secondary objectives of overall survival and the objective response rate, compared to sunitinib, while demonstrating a favourable safety profile.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.